Compare Flux Power Holdings Inc (FLUX) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flux Power Holdings Inc vs Gilead Sciences, Inc. — how do they compare? Flux Power Holdings Inc trades at $0.68 (market cap $15.37M), while Gilead Sciences, Inc. trades at $135.66 (market cap $163.51B). The key difference: Gilead Sciences, Inc. is far larger — about 10638.3× Flux Power Holdings Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Flux Power Holdings Inc pays none. Which is the better fit depends on your goals.
| FLUX | GILD | |
|---|---|---|
Market Cap | $15.37M | $163.51B |
Sector | Utilities | Health |
52-Week High | $6.66 | $155.80 |
52-Week Low | $0.71 | $108.22 |
Enterprise Value | $21.53M | $178.05B |
Dividend Yield | — | 2.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLUX trades at $0.689, down 3.85% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $6.67 million in 2025 and a negative net income margin of -12.48% in 2026, though revenue remains substantial. Recent news highlights product innovation with the launch of SkyEMS 3.0 and new executive appointments aimed at growth. Analyst consensus is unanimously bullish with 6 buy ratings.
The outlook is mixed: strong analyst support and strategic developments offer upside potential, but persistent losses and bearish technicals pose significant risks. Investors must weigh growth initiatives against profitability challenges and market volatility.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Flux Power Holdings Inc
Flux Power designs and manufactures lithium-ion battery packs for industrial vehicles. Its sustainable energy solutions power material handling equipment like forklifts and airport ground support vehicles.
Read more on FLUX →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
